MarketMoodz
Novo Nordisk Wins FDA Nod for First Weekly Basal Insulin, Awiqli
The FDA approved Novo Nordisk's Awiqli (insulin icodec-abae), the first once-weekly basal insulin for adults with Type 2 diabetes. The move could shift prescribing patterns away from daily basal insulins and influence payer negotiations as longer-interval therapies enter the market.
Key Takeaways
- Awiqli is the first once-weekly basal insulin approved for adults with Type 2 diabetes.
- ONWARDS Phase 3a enrolled about 2,680 adults and showed HbA1c reductions comparable to daily basal insulin with a similar safety profile.
- Awiqli is available in a U-700 concentration and delivered via a prefilled FlexTouch pen.
- US rollout is expected in coming months, with EU approvals already granted (indications vary).
- Weekly therapy could improve adherence versus daily regimens, potentially expanding Novo Nordisk's addressable market and payer dynamics.
People Involved
- Julio Rosenstock ONWARDS lead investigator
- Anna Windle Novo Nordisk Inc. executive
Entities Involved
- Novo Nordisk A/S Developer of Awiqli; insulin manufacturer
- Novo Nordisk Inc. US subsidiary; executive cited in communications
- ONWARDS Phase 3a program Clinical program evaluating Awiqli
MarketMoodz Analysis
For investors, Awiqli represents a potential expansion of Novo Nordisk's diabetes franchise. If payer coverage expands and uptake grows, weekly dosing could lift patient adherence and broaden total addressable market. Early trial data from ONWARDS show HbA1c reductions comparable to daily basal insulin with a similar safety profile, supporting near-term revenue potential, though US rollout timing remains a key determinant.
Historically, insulin regimens have favored daily dosing with adherence challenges. A weekly insulin reverses some adherence friction, akin to long-acting injectables in other therapeutic areas. If approved in the US with favorable payer coverage, Awiqli could pressure competitors to advance long-acting basal options and influence pricing dynamics.
What to watch next: US launch timing, payer negotiations, real-world adherence data, potential pricing strategy, and any new head-to-head data versus daily basal insulins.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial